OGN – Organon & Co.

OGN — Price & Forward EBITDA

Forward EBITDA (M)

Float Short %

7.46

Margin Of Safety %

Put/Call OI Ratio

0.81

EPS Next Q Diff

0.33

EPS Last/This Y

2.75

EPS This/Next Y

0.26

Price

5.84

Target Price

9.67

Analyst Recom

3.5

Performance Q

-17.63

Upside

171.2%

Beta

0.64

Ticker: OGN

20 items of 1

Date	Symbol	Latest	P/C OI	P/C Vol	Total OI
2026-02-27	OGN	7.3	0.80	0.77	110407
2026-03-02	OGN	7.2	0.80	0.62	110622
2026-03-03	OGN	6.9	0.80	0.59	110748
2026-03-04	OGN	6.86	0.80	0.66	110903
2026-03-05	OGN	6.72	0.79	1.27	110685
2026-03-06	OGN	6.56	0.79	0.42	111778
2026-03-09	OGN	6.53	0.79	1.06	112355
2026-03-10	OGN	6.47	0.78	0.67	112350
2026-03-11	OGN	6.41	0.78	0.82	112462
2026-03-12	OGN	6.33	0.77	1.05	111708
2026-03-13	OGN	6.33	0.77	1.02	111708
2026-03-17	OGN	6.39	0.75	0.47	111046
2026-03-18	OGN	6.22	0.77	0.38	112909
2026-03-19	OGN	6.26	0.76	1.65	113054
2026-03-20	OGN	6.03	0.76	0.08	113233
2026-03-23	OGN	6.09	0.89	0.11	81085
2026-03-24	OGN	6.12	0.86	0.20	82872
2026-03-25	OGN	6.1	0.84	0.25	83708
2026-03-26	OGN	6.06	0.82	0.30	84906
2026-03-27	OGN	5.84	0.81	0.74	85984
Date	Symbol	Latest	P/C OI	P/C Vol	Total OI

20 items 1 of 1

20 items of 1

Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year
2026-02-27	OGN	7.29	-17.5	-	3.50
2026-03-02	OGN	7.20	-14.7	-	3.50
2026-03-03	OGN	6.90	-15.0	-	3.50
2026-03-04	OGN	6.87	-15.0	-	3.47
2026-03-05	OGN	6.71	-15.0	-	3.47
2026-03-06	OGN	6.57	-15.0	-	3.47
2026-03-09	OGN	6.54	-15.0	-	3.47
2026-03-10	OGN	6.48	-15.0	-	3.47
2026-03-11	OGN	6.40	-15.0	-	3.47
2026-03-12	OGN	6.33	-15.0	-	3.47
2026-03-13	OGN	6.36	-15.0	-	3.47
2026-03-17	OGN	6.39	-15.0	-	3.47
2026-03-18	OGN	6.22	-15.0	-	3.47
2026-03-19	OGN	6.26	-15.0	-	3.47
2026-03-20	OGN	6.04	-15.0	-	3.47
2026-03-23	OGN	6.09	-15.0	-	3.47
2026-03-24	OGN	6.11	-15.0	-	3.47
2026-03-25	OGN	6.10	-15.0	-	3.47
2026-03-26	OGN	6.06	-15.0	-	3.47
2026-03-27	OGN	5.84	-15.0	-	3.47
Date	Ticker	Price	Current Quarter Growth Estimate	EBIT Estimation	Average EPS Estimate Current Year

20 items 1 of 1

20 items of 1

Date	Ticker	Insider Transactions	Institutional Transactions	Float Short
2026-02-27	OGN	5.78	-4.62	6.77
2026-03-02	OGN	5.78	-1.04	6.77
2026-03-03	OGN	5.78	-1.04	6.77
2026-03-04	OGN	5.78	-1.04	6.77
2026-03-05	OGN	5.77	-1.04	6.77
2026-03-06	OGN	5.78	-1.04	6.77
2026-03-09	OGN	5.78	-1.51	6.77
2026-03-10	OGN	5.78	-1.51	6.77
2026-03-11	OGN	5.79	-1.51	6.28
2026-03-12	OGN	5.78	-1.51	6.28
2026-03-13	OGN	5.78	-1.51	6.28
2026-03-17	OGN	5.78	-1.46	6.28
2026-03-18	OGN	5.78	-1.46	6.28
2026-03-19	OGN	5.77	-1.46	6.28
2026-03-20	OGN	5.78	-1.46	6.28
2026-03-23	OGN	5.78	-1.53	6.28
2026-03-24	OGN	5.78	-1.53	6.28
2026-03-25	OGN	5.78	-1.53	7.46
2026-03-26	OGN	5.78	-1.53	7.46
2026-03-27	OGN	5.78	-1.53	7.46
Date	Ticker	Insider Transactions	Institutional Transactions	Float Short

20 items 1 of 1

Last Quarter Act. EPS

0.61

Avg. EPS Est. Current Quarter

0.87

Avg. EPS Est. Next Quarter

0.94

Insider Transactions

5.78

Institutional Transactions

-1.53

Beta

0.64

Average Sales Estimate Current Quarter

1498

Average Sales Estimate Next Quarter

1568

Fair Value

9.99

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

85.2

Max Drawdown 5-Year %

Target Price

9.67

P/E

8.15

Forward P/E

1.57

PEG

0.6

P/S

0.24

P/B

2.02

P/Free Cash Flow

2.83

EPS

0.72

Average EPS Est. Cur. Y

3.47

EPS Next Y. (Est.)

3.73

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

3.01

Relative Volume

0.59

Return on Equity vs Sector %

-2.5

Return on Equity vs Industry %

-11.8

EPS 1 7Days Diff

EPS 1 30Days Diff

-0.4

EBIT Estimation

◆ OGN Healthcare

$5.84

📉

Swing / Pullback

Buy the dip on strong trends

N/A

WEAK

Trend

20/20

Pullback

7/25

Volume

11/15

Valuation

18/20

TP/AR

0/10

Options

5/10

RSI

25.6

Range 1M

7.8%

🚀

Momentum Growth

Ride accelerating trends

N/A

WEAK

Momentum

8/25

Growth

1/30

Estimates

3/20

Inst/Vol

0/15

Options

3/10

EPS Yr

-5.3%

EPS NY

7.3%

52W%

1.3%

💎

Long-Term Value

Quality companies, undervalued

N/A

WEAK

🟢 BUY +687% upside

Quality

14/30

Valuation

27/30

Growth

2/25

Stability

4/10

LT Trend

4/5

Upside

+687%

Quality

MoS

71%

Organon & Co.

Sector: Healthcare

Industry: Drug Manufacturers - General

Employees: 10000

Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1923 and is headquartered in Jersey City, New Jersey.

OGN

Latest News

—

Caricamento notizie per OGN…

stock quote shares OGN – Organon & Co. Stock Price stock today

news today OGN – Organon & Co. stock forecast ,stock prediction 2023 2024 2025

marketwatch OGN – Organon & Co. yahoo finance google finance

stock history OGN – Organon & Co. invest stock market

stock prices OGN premarket after hours

ticker OGN fair value insiders trading

OGN – Organon & Co.

Float Short %

Margin Of Safety %

Put/Call OI Ratio

EPS Next Q Diff

EPS Last/This Y

EPS This/Next Y

Price

Target Price

Analyst Recom

Performance Q

Upside

Beta

Ticker: OGN

Last Quarter Act. EPS​

Avg. EPS Est. Current Quarter

Avg. EPS Est. Next Quarter

Insider Transactions

Institutional Transactions

Beta

Average Sales Estimate Current Quarter

Average Sales Estimate Next Quarter

Fair Value

Quality Score

Growth Score

Sentiment Score

Actual DrawDown %

Max Drawdown 5-Year %

Target Price

P/E

Forward P/E

PEG

P/S

P/B

P/Free Cash Flow

EPS

Average EPS Est. Cur. Y​

EPS Next Y. (Est.)

Target Price Estimates Raised

Target Price Estimates Lowered

Profit Margin

Relative Volume

Return on Equity vs Sector %

Return on Equity vs Industry %

EPS 1 7Days Diff

EPS 1 30Days Diff

EBIT Estimation

Latest News

Last Quarter Act. EPS

Average EPS Est. Cur. Y